Or, no paywall: https://www.reuters.com/business/healthcare-pharmaceuticals/...
> The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected.
Contrasted with Lilly's already approved Zepbound (tirzepatide):
> Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly 23% in clinical trials.
Or, no paywall: https://www.reuters.com/business/healthcare-pharmaceuticals/...
> The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected.
Contrasted with Lilly's already approved Zepbound (tirzepatide):
> Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly 23% in clinical trials.